Radiopharmaceutical company Telix Pharmaceuticals Ltd. is continuing its buying spree to shore up dominance in the radiopharmaceutical market with its latest acquisition of RLS Radiopharmacies for $250 million to expand its U.S. manufacturing presence and establish a next-generation radiometal production network.
Chengdian (Suzhou) Biopharmaceutical Co. Ltd. has received IND clearance from the FDA, allowing it to initiate a first-in-human phase I trial of CD-001.
For once, the EMA appears to have pipped the U.S. FDA to the post, with Pfizer Inc.’s hemophilia A and B therapy Hympavzi (marstacimab) recommended for approval in Europe on Sept. 20, while the U.S. PDUFA date is set for the fourth quarter of the year.
Work at Innovstone Therapeutics Ltd. has led to the identification of new dihydrothienopyrimidine derivatives acting as phosphodiesterase PDE4B inhibitors.
A Hitgen Ltd. patent details aromatic-ring compounds acting as E3 ubiquitin-protein ligase (TRIM21) ligands reported to be useful for the treatment of cancer.
Zydus Lifesciences Ltd. has patented new compounds acting as ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors.
Innate Pharma SA has obtained IND clearance from the FDA for IPH-4502, its novel and differentiated topoisomerase I inhibitor antibody-drug conjugate (ADC) conjugated to exatecan targeting Nectin-4 in solid tumors. In nonclinical models, IPH-45 was well tolerated and showed antitumor efficacy in vitro and in vivo.
Gastric cancer (GC) is among the most malignant tumors in terms of incidence and mortality. Early diagnosis can improve the survival rate of patients, but there is a lack of effective biomarkers for the diagnosis and prognosis of GC. Zinc finger protein 1 homologue (ZFP1) plays an important role in transcriptional regulation during embryonic development. Its homologue, MLLT10, had been found to promote carcinogenesis in leukemia and colon cancer, but limited knowledge exists on the role of ZFP1 in cancer.
Although details are scant, Shanghai Fosun Pharmaceutical Co. Ltd. plans to buy out partner Kite Pharma Inc. (now Gilead Sciences Inc.) in the Fosun Pharma Kite Biotechnology Co. Ltd. joint venture for $27 million.
Tambo Inc. has described conjugates consisting of payloads covalently linked to trans-cyclooctene through a linker reported to be useful for the treatment of cancer.
RSS
